Truist raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $86 from $80 on January 8, maintaining a Buy rating. The firm updated its model but stated its fundamental views remain unchanged from 2025.
On January 12, BridgeBio Pharma provided a significant operational update at the 44th Annual J.P. Morgan Healthcare Conference. For its drug Attruby, the company announced preliminary unaudited revenues of $146.0 million for the fourth quarter of 2025. Full-year 2025 product revenue totaled $362.4 million.
Over 6,000 unique prescriptions for Attruby were written by the end of 2025. The drug is a first-choice treatment for newly diagnosed ATTR-CM patients.
BridgeBio Pharma develops therapies for genetic diseases and cancers. It supports its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT). BBOT advances precision cancer treatments targeting oncogenes like RAS and PI3K into clinical trials.